AP982A - Quinoxalinediones. - Google Patents

Quinoxalinediones. Download PDF

Info

Publication number
AP982A
AP982A APAP/P/1998/001201A AP9801201A AP982A AP 982 A AP982 A AP 982A AP 9801201 A AP9801201 A AP 9801201A AP 982 A AP982 A AP 982A
Authority
AP
ARIPO
Prior art keywords
formula
compound
pharmaceutically acceptable
acceptable salt
solvate
Prior art date
Application number
APAP/P/1998/001201A
Other languages
English (en)
Inventor
Alan Stobie
Elisabeth Colette Louise Gautier
David Charles Waite
Robert James Crook
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Priority claimed from PCT/EP1997/000995 external-priority patent/WO1997032873A1/en
Priority claimed from GBGB9715783.8A external-priority patent/GB9715783D0/en
Application granted granted Critical
Publication of AP982A publication Critical patent/AP982A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Luminescent Compositions (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
APAP/P/1998/001201A 1997-02-27 1997-02-27 Quinoxalinediones. AP982A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP1997/000995 WO1997032873A1 (en) 1996-03-09 1997-02-27 Quinoxalinediones
GBGB9715783.8A GB9715783D0 (en) 1997-02-27 1997-07-25 Quinoxalinediones

Publications (1)

Publication Number Publication Date
AP982A true AP982A (en) 2001-07-16

Family

ID=10816496

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1998/001201A AP982A (en) 1997-02-27 1997-02-27 Quinoxalinediones.

Country Status (14)

Country Link
US (1) US6333326B1 (uk)
KR (1) KR100375112B1 (uk)
AP (1) AP982A (uk)
AU (1) AU723467B2 (uk)
DZ (1) DZ2437A1 (uk)
EA (1) EA001658B1 (uk)
GT (1) GT199800045A (uk)
HK (1) HK1025317A1 (uk)
IL (1) IL131120A0 (uk)
IS (1) IS5142A (uk)
MA (1) MA26474A1 (uk)
OA (1) OA11189A (uk)
PL (1) PL335501A1 (uk)
UA (1) UA58534C2 (uk)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2002133666A (ru) * 2000-05-19 2007-05-10 Мерк Патент ГмбХ (DE) Производные триазола
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
US8603980B2 (en) 2007-01-16 2013-12-10 The Johns Hopkins University Glutamate receptor antagonists and methods of use
CN104370834B (zh) 2007-05-17 2017-04-19 株式会社半导体能源研究所 三唑衍生物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0556293A1 (en) * 1990-10-30 1993-08-25 Minnesota Mining & Mfg PROCESS FOR THE PREPARATION OF BISPHENOL FLUORENE COMPOUNDS.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158846A (en) 1990-10-29 1992-10-27 Olin Corporation Electrostatic color printing system utilizing an image transfer belt
EP0556393B1 (en) * 1990-11-06 2000-07-26 Yamanouchi Pharmaceutical Co. Ltd. Fused pyrazine derivative
GB9605027D0 (en) 1996-03-09 1996-05-08 Pfizer Ltd Quinoxalinediones

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0556293A1 (en) * 1990-10-30 1993-08-25 Minnesota Mining & Mfg PROCESS FOR THE PREPARATION OF BISPHENOL FLUORENE COMPOUNDS.

Also Published As

Publication number Publication date
UA58534C2 (uk) 2003-08-15
HK1025317A1 (en) 2000-11-10
IS5142A (is) 1999-07-30
KR20000075717A (ko) 2000-12-26
EA199900688A1 (ru) 2000-04-24
IL131120A0 (en) 2001-01-28
EA001658B1 (ru) 2001-06-25
PL335501A1 (en) 2000-04-25
AU723467B2 (en) 2000-08-24
US6333326B1 (en) 2001-12-25
GT199800045A (es) 1999-08-20
AU6827998A (en) 1998-09-18
DZ2437A1 (fr) 2003-01-11
OA11189A (en) 2003-05-14
MA26474A1 (fr) 2004-12-20
KR100375112B1 (ko) 2003-03-08

Similar Documents

Publication Publication Date Title
AP495A (en) Piperidine derivatives
JP2978566B2 (ja) ノイロキニンレセプター拮抗薬としての５−アザビシクロ［３．１．０］ヘキシルアルキル−２−ピペリドンおよび−グルタルイミド
EP1716135B1 (en) Piperidinylcarbonyl-pyrrolidines and their use as melanocortin agonists
US6376490B1 (en) Quinoxalinediones
JPH08511032A (ja) ５−アリールインドール誘導体
JP2009541463A (ja) ピペリジンまたはピロリジンの尿素誘導体、これらの調製およびこれらの治療的使用
JP2003034689A (ja) ４−複素環式環縮合アリールピペリジン誘導体
EP2623504A1 (de) 5,6-Disubstituierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen
TWI826406B (zh) 作為血管升壓素Ｖ１ａ受體拮抗劑之三唑並苯並吖呯
JP3026945B2 (ja) ３−アザ及び３−オキサピペリドンタキキニン拮抗薬
TW201722936A (zh) Ｃｇｒｐ受體拮抗劑
EP0973766B1 (en) Quinoxalinediones
AP982A (en) Quinoxalinediones.
WO2021159372A1 (zh) Jak抑制剂在制备治疗jak激酶相关疾病药物中的应用
AU688591B2 (en) Quinoxaline derivatives useful in therapy
JP2022525697A (ja) Ｄｒｐ１－フィラミン複合体形成阻害剤
TW201726687A (zh) Ｎ－（２－（２－胺基－６－取代－４，４ａ，５，６－四氫哌喃并［３，４－ｄ］［１，３］－８ａ（８Ｈ）－基）－噻唑－４－基）醯胺類
CZ9903052A3 (cs) Chinoxalindiony, způsoby a meziprodukty pro jejich výrobu, jejich použití, farmaceutické přípravky na jejich bázi a způsoby léčení
MXPA99007937A (en) Quinoxalinediones
JP2002532525A (ja) ジヒドロピリミジンおよびその使用
JP2007516179A (ja) Ｇタンパク質の機能を阻害するために有用な三環式アミドの代謝産物および増殖性疾患の処置方法
BR112016012182B1 (pt) Composto e seu uso